Find Clinical Trial

A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors


← Back
Study Phase

Phase 1-2

Therapeutic Area

Cancers

IndicationSolid tumors
SponsorInstitut de Recherches Internationales Servier (I.R.I.S) and Pieris Pharmaceuticals
Active substance/
Medical device

Solid tumors

Active Substance CodePRS-344/S095012
Protocol CodeCL1-95012-001
EudraCT Code2019-003456-36
NCT CodeNCT05159388


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility